Endogenex develops a minimally invasive procedure that targets cellular pathology in the duodenum to restore metabolic signaling. Its Endogenex System applies highly controlled, non-thermal pulsed electric fields to the mucosa and submucosa to support healthy cell regeneration. The company is clinical-stage and has evaluated the technology in feasibility studies including REGENT-1 US, REGENT-1 Australia, and EMINENT in the Netherlands, with preliminary outcomes presented at medical conferences. Endogenex is led by CEO Stacey Pugh and is based in Minneapolis, MN. In June 2024 it closed an $88M Series C and in March 2026 raised a $50M Series C extension, bringing total Series C financing to $138M.

Total raised

$138M

Funding rounds

2

Latest round

Series C

Latest activity

Mar 2026